We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where ...

Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

Metsera (NASDAQ:MTSR) was able to complete its initial public offering [IPO] back on February 3rd of 2025. Before taking expenses into account, it was able to generate net proceeds of about $316.2 ...

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside.

three insiders acquired a total of $94.22 million in Metsera shares at $18 per share during the company’s initial public offering. The company raised $257 million during its IPO, pricing shares ...

Metsera Inc. MTSR, a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in ...

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity could be "a multibillion ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is ...